Publications
기타논문
Date: January 2011
Journal: Phytotherapy Research Volume 25, Issue 1, January 2011, Pages 1-10 , Doi: 10.1002/ptr.3224
2011 | Antiangiogenic phytochemicals and medicinal herbs…
- Jeong, S.-J.a, Koh, W.a, Lee, E.-O.a, Lee, H.-J.a, Lee, H.-J.a, Bae, H.a, Lü, J.b, Kim, S.-H.a
Abstract
Medicinal herbs and their phytochemicals are potential novel leads for developing antiangiogenic drugs. This review aims to assess the current status of research with medicinal herbs and their phytochemicals for the development of antiangiogenic agents for cancer and other angiogenesis-related diseases including inflammation, diabetic retinopathy, endometriosis and obesity. Most studies reviewed have focused on vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR-2) signaling for endothelial response processes and have led to the identification of many potential antiangiogenic agents. Since human clinical trials with antiangiogenic modalities targeting VEGF/VEGFR-2 signaling have shown limited efficacy and occasional toxic side effects, screening strategies for herbal phytochemicals based on other signaling pathways important for cancer-endothelial and stromal crosstalks should be emphasized in the future. © 2010 John Wiley & Sons, Ltd.
Author keywords
angiogenic diseases; antiangiogenesis; medical herbs; phytochemicals; VEGF/VEGFR
Indexed keywords
EMTREE drug terms: angiostatin; antirheumatic agent; apigenin; bevacizumab; caffeic acid; campesterol; celastrol; coumarin derivative; curcumin; delphinidin; ellagic acid; endostatin; epigallocatechin gallate; farnesiferol c; fisetin; flavone; gallic acid; genistein; guggulsterone; hypericin; paeoniflorin; plant medicinal product; quercetin; resveratrol; scopolin; solimastat; sulforaphane; tannin; thymoquinone; unclassified drug; unindexed drug
EMTREE medical terms: antiangiogenic activity; clinical trial; diabetic retinopathy; drug mechanism; drug screening; endometriosis; herb; human; inflammation; metastasis; neoplasm; nonhuman; obesity; review; rheumatoid arthritis
MeSH: Angiogenesis Inhibitors; Animals; Diabetic Retinopathy; Endometriosis; Female; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Obesity; Phytotherapy; Plants, Medicinal; Signal Transduction; Vascular Endothelial Growth Factor A
Medline is the source for the MeSH terms of this document.
Chemicals and CAS Registry Numbers: angiostatin, 172642-30-7, 86090-08-6; apigenin, 520-36-5; bevacizumab, 216974-75-3; caffeic acid, 27323-69-9, 331-39-5; campesterol, 474-62-4; celastrol, 34157-83-0; curcumin, 458-37-7; delphinidin, 528-53-0; ellagic acid, 476-66-4; endostatin, 187888-07-9; epigallocatechin gallate, 989-51-5; fisetin, 528-48-3; flavone, 525-82-6; gallic acid, 149-91-7; genistein, 446-72-0; guggulsterone, 39025-23-5, 39025-24-6, 95975-55-6; hypericin, 548-04-9; paeoniflorin, 23180-57-6; quercetin, 117-39-5; resveratrol, 501-36-0; scopolin, 531-44-2; sulforaphane, 142925-33-5, 4478-93-7; tannin, 1401-55-4; thymoquinone, 490-91-5;Angiogenesis Inhibitors; Vascular Endothelial Growth Factor A